Drug Trial Radar · NCT07227402
A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033)
Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
904
Planned (sponsor's estimate)
Start
Nov 26, 2025
Primary completion
Feb 27, 2032
Study completion Mar 21, 2033
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- Collaborators
- Exelixis
- First posted
- Nov 12, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Researchers are looking for more ways to treat advanced renal cell carcinoma (RCC) that is recurrent. Researchers want to learn if recurrent advanced renal cell carcinoma (RCC) responds (gets smaller or goes away) after treatment with belzutifan (MK-6482) and zanzalintinib compared to cabozantinib. The goal of this study is to learn if: People who take belzutifan and zanzalintinib live longer overall and without the cancer getting worse than people who take cabozantinib.
Conditions
- Renal Cell Carcinoma
Interventions
BelzutifanDrug
Administered orally QD
ZanzalintinibDrug
Administered orally QD
CabozantinibDrug
Administered orally QD
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression Free Survival (PFS)Time frame: Up to approximately 73 months
- Overall Survival (OS)Time frame: Up to approximately 73 months
Locations
129 sites in 24 countries. Site status is shown where the registry gives one.
Alaska Oncology and Hematology ( Site 0133)
Anchorage, Alaska · Recruiting
Providence Medical Foundation ( Site 0141)
Fullerton, California · Recruiting
USC Norris Comprehensive Cancer Center ( Site 0126)
Los Angeles, California · Recruiting
Cedars-Sinai Medical Center ( Site 0112)
Los Angeles, California · Recruiting
New England Cancer Specialists ( Site 0132)
Westbrook, Maine · Recruiting
Greater Baltimore Medical Center ( Site 0145)
Baltimore, Maryland · Recruiting
Metro-Minnesota Community Clinical Oncology ( Site 0144)
Saint Louis Park, Minnesota · Recruiting
Oncology Hematology West P.C. dba Nebraska Cancer Specialists ( Site 0131)
Omaha, Nebraska · Recruiting
Carolina Oncology Specialists, PA ( Site 9002)
Charlotte, North Carolina · Recruiting
Thompson Cancer Survival Center ( Site 0125)
Knoxville, Tennessee · Recruiting
Tennessee Oncology, PLLC - Elliston Place Plaza Medical Oncology & Hematology ( Site 9000)
Nashville, Tennessee · Recruiting
Hospital Privado Universitario de Córdoba ( Site 0207)
Córdoba, Argentina · Recruiting
Hospital Italiano de Buenos Aires. ( Site 0203)
Caba, Buenos Aires, Argentina · Recruiting
Asociación de Beneficencia Hospital Sirio Libanés ( Site 0205)
Caba, Buenos Aires, Argentina · Recruiting
Hospital Aleman ( Site 0204)
CABA, Buenos Aires, Argentina · Recruiting
Instituto Alexander Fleming ( Site 0202)
CABA, Buenos Aires, Argentina · Recruiting
Hospital Universitario Austral ( Site 0212)
Pilar, Buenos Aires, Argentina · Recruiting
Centro de Educación Médica e Investigaciones clínicas "Dr. Norberto Quirno" (CEMIC) ( Site 0208)
Caba., Buenos Aires F.D., Argentina · Recruiting
Sanatorio Parque ( Site 0201)
Rosario, Santa Fe Province, Argentina · Recruiting
Instituto de Oncología de Rosario ( Site 0209)
Rosario, Santa Fe Province, Argentina · Recruiting
Macquarie University-MQ Health Clinical Trials Unit ( Site 2100)
Sydney, New South Wales, Australia · Recruiting
Medizinische Universitat Wien ( Site 0601)
Vienna, Austria · Recruiting
Ordensklinikum Linz GmbH Elisabethinen-Urologie ( Site 0600)
Linz, Upper Austria, Austria · Recruiting
Cliniques Universitaires Saint-Luc ( Site 0703)
Brussels, Bruxelles-Capitale, Region de, Belgium · Recruiting
Ziekenhuis Oost-Limburg, Campus St.-Jan ( Site 0701)
Genk, Limburg, Belgium · Recruiting
UZ Gent ( Site 0702)
Ghent, Oost-Vlaanderen, Belgium · Recruiting
UZ Leuven ( Site 0700)
Leuven, Vlaams-Brabant, Belgium · Recruiting
IPC - MT Instituto de Pesquisas Clínicas do Mato Grosso ( Site 0305)
Cuiabá, Mato Grosso, Brazil · Recruiting
Liga Norte Riograndense Contra o Câncer ( Site 0307)
Natal, Rio Grande do Norte, Brazil · Recruiting
Hospital Moinhos de Vento ( Site 0309)
Porto Alegre, Rio Grande do Sul, Brazil · Recruiting
Fundação Faculdade Regional de Medicina de São José do Rio Preto ( Site 0302)
São José do Rio Preto, São Paulo, Brazil · Recruiting
Hospital Alemao Oswaldo Cruz ( Site 0311)
São Paulo, São Paulo, Brazil · Recruiting
Oncocentro Valdivia ( Site 0408)
Valdivia, Los Ríos Region, Chile · Recruiting
Fundacion Arturo Lopez Perez ( Site 0401)
Santiago, Region M. de Santiago, Chile · Recruiting
Centro de Investigacion Clinica UC CICUC ( Site 0402)
Santiago, Region M. de Santiago, Chile · Recruiting
Klinički bolnički centar Sestre milosrdnice ( Site 0801)
Zagreb, City of Zagreb, Croatia · Recruiting
Klinički bolnički centar Zagreb ( Site 0800)
Zagreb, City of Zagreb, Croatia · Recruiting
Klinički Bolnički Centar Split ( Site 0802)
Split, Split-Dalmatia County, Croatia · Recruiting
Nemocnice České Budějovice ( Site 0905)
České Budějovice, Czechia · Recruiting
Fakultni nemocnice Hradec Kralove ( Site 0902)
Hradec Králové, Czechia · Recruiting
Showing 40 of 129 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.